白蛋白结合型紫杉醇治疗晚期宫颈癌的效果及安全性

Efficacy and safety of Albumin-bound Paclitaxel in treatment of patients with advanced cervical cancer

目的分析使用白蛋白结合型紫杉醇对晚期宫颈癌患者的疗效及安全性。方法选取2012年5月~2015年8月解放军总医院治疗的晚期妇科癌症患者23例,所有患者均采用白蛋白结合型紫杉醇进行化疗,药物用量为175 mg/m^2,滴注时间为30 min,第1天滴注,21 d为1个疗程,所有患者均完成2个疗程以上化疗,治疗后评价其疗效。结果治疗后晚期宫颈癌患者完全缓解1例,部分缓解15例,病情稳定5例,进展2例。总有效率为69.6%。白蛋白结合型紫杉醇的安全性评估发现,患者血液毒性较重,胃肠道毒性、肝肾毒性、神经毒性较轻。结论使用白蛋白结合型紫杉醇对晚期宫颈癌患者进行治疗,其有效性、安全性均较高。

Objective To analyze the efficacy and safety of Paclitaxel in patients with advanced cervical cancer. Methods From May 2012 to August 2015, 23 patients with advanced gynecologic cancer treated in Chinese PLA General Hospital were selected, all patients were given the albumin-bound Paclitaxel chemotherapy, drug dosage was 175 mg/m2, infusion time was 30 rain. Infusion at the first day of Chemotherapy, with 21 days for a course of treatment, 2 or more cycles of chemotherapy were carried out in all patients. Curative effect was evaluated after treatment. Results After treatment, 1 cases of complete remission, 15 cases of partial remission, 5 cases of stable disease, 2 eases of progress, and the total effective rate was 69.6%. Safety evaluation of albumin-bound Paelitaxel found that, the blood toxicity was relatively heavy, toxicity of gastrointestinal, liver and kidney, and neurotoxicity were milder. Conclusion Albuminbound Paelitaxel is effective and safe for patients with advanced cervical cancer.